NEU 0.35% $20.17 neuren pharmaceuticals limited

ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-45

  1. 755 Posts.
    lightbulb Created with Sketch. 83
    Interesting mention about biomarkers. Anavex actually had two biomarkers that produced positive results in their trial.
    Their effect size was larger too.

    Still bullish on Neuren, but I also picked up some Anavex shares overnight.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.